Involvement of AGE and Its Receptors in the Pathogenesis of Hypertension in Elderly People and Its Treatment

Abstract

Both systolic and diastolic blood pressures increase with age up to 50 to 60 years of age. After 60 years of age systolic pressure rises to 84 years of age but diastolic pressure remains stable or even decreases. In the oldest age group (85–99 years), the systolic blood pressure (SBP) is high and diastolic pressure (DBP) is the lowest. Seventy percent of people older than 65 years are hypertensive. This paper deals with the role of advanced glycation end products (AGE) and its cell receptor (RAGE) and soluble receptor (sRAGE) in the development of hypertension in the elderly population. Plasma/serum levels of AGE are higher in older people as compared with younger people. Serum levels of AGE are positively correlated with age, arterial stiffness, and hypertension. Low serum levels of sRAGE are associated with arterial stiffness and hypertension. Levels of sRAGE are negatively correlated with age and blood pressure. Levels of sRAGE are lower in patients with arterial stiffness and hypertension than patients with high levels of sRAGE. AGE could induce hypertension through numerous mechanisms including, cross-linking with collagen, reduction of nitric oxide, increased expression of endothelin-1, and transforming growth factor-β (TGF-β). Interaction of AGE with RAGE could produce hypertension through the generation of reactive oxygen species, increased sympathetic activity, activation of nuclear factor-kB, and increased expression of cytokines, cell adhesion molecules, and TGF- β. In conclusion, the AGE–RAGE axis could be involved in hypertension in elderly people. Treatment for hypertension in elderly people should be targeted at reduction of AGE levels in the body, prevention of AGE formation, degradation of AGE in vivo, downregulation of RAGE expression, blockade of AGE–RAGE interaction, upregulation of sRAGE expression, and use of antioxidants.

Keywords

advanced glycation end products - cell receptor for AGE - soluble receptor for AGE - elderly hypertension - arterial stiffness - AGE cross-link with collagen

Disclosure

None.

Publikationsverlauf

Artikel online veröffentlicht:
08. September 2022

• References

• 1 Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71 (06) e13-e115
• 2 DeGuire J, Clarke J, Rouleau K, Roy J, Bushnik T. Blood pressure and hypertension. Health Rep 2019; 30 (02) 14-21
• 3 American College of Cardiology. 2017 guideline for prevention, detection, evaluation, and management of high blood pressure in adults. Accessed August 10, 2022 at: https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Guidelines/2017/Guidelines_Made_Simple_2017_HBP.pdf
• 4 Zdrojewski T, Wizner B, Więcek A. et al. Prevalence, awareness, and control of hypertension in elderly and very elderly in Poland: results of a cross-sectional representative survey. J Hypertens 2016; 34 (03) 532-538 , discussion 538
• 5 Muli S, Meisinger C, Heier M, Thorand B, Peters A, Amann U. Prevalence, awareness, treatment, and control of hypertension in older people: results from the population-based KORA-age 1 study. BMC Public Health 2020; 20 (01) 1049
• 6 Buford TW. Hypertension and aging. Ageing Res Rev 2016; 26: 96-111
• 7 Troen BR. The biology of aging. Mt Sinai J Med 2003; 70 (01) 3-22
• 8 Lionakis N, Mendrinos D, Sanidas E, Favatas G, Georgopoulou M. Hypertension in the elderly. World J Cardiol 2012; 4 (05) 135-147
• 9 Oliveros E, Patel H, Kyung S. et al. Hypertension in older adults: Assessment, management, and challenges. Clin Cardiol 2020; 43 (02) 99-107
• 10 Prasad K, Dhar I, Zhou Q, Elmoselhi H, Shoker M, Shoker A. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease. Mol Cell Biochem 2016; 423 (1-2): 105-114
• 11 McNair ED, Wells CR, Mabood Qureshi A. et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol 2010; 33 (11) 678-685
• 12 Caspar-Bell G, Dhar I, Prasad K. Advanced glycation end products (AGEs) and its receptors in the pathogenesis of hyperthyroidism. Mol Cell Biochem 2016; 414 (1-2): 171-178
• 13 Prasad K, Sarkar A, Zafar MA. et al. Advanced Glycation End Products and its Soluble Receptors in the Pathogenesis of Thoracic Aortic Aneurysm. Aorta (Stamford) 2016; 4 (01) 1-10
• 14 Prasad K. Blood Pressure Regulation. In: Dieter RS, Dieter RA, Dieter III RA. eds. Peripheral Arterial Disease. New York, NY: The McGraw-Hill companies; 2009: 113-123
• 15 Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107 (22) 2864-2869
• 16 Mitchell GF, Lacourcière Y, Ouellet JP. et al. Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship. Circulation 2003; 108 (13) 1592-1598
• 17 Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 2003; 107 (03) 490-497
• 18 Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 2005; 45 (06) 1050-1055
• 19 Vatner SF, Zhang J, Vyzas C, Mishra K, Graham RM, Vatner DE. Vascular Stiffness in Aging and Disease. Front Physiol 2021; 12: 762437
• 20 Maurel E, Shuttleworth CA, Bouissou H. Interstitial collagens and ageing in human aorta. Virchows Arch A Pathol Anat Histopathol 1987; 410 (05) 383-390
• 21 Sell DR, Monnier VM. Molecular basis of arterial stiffening: role of glycation - a mini-review. Gerontology 2012; 58 (03) 227-237
• 22 Wang M, Zhang J, Spinetti G. et al. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol 2005; 167 (05) 1429-1442
• 23 Wang M, Zhang J, Telljohann R. et al. Chronic matrix metalloproteinase inhibition retards age-associated arterial proinflammation and increase in blood pressure. Hypertension 2012; 60 (02) 459-466
• 24 McEniery CM, , Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR. ACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005; 46 (09) 1753-1760
• 25 Oelze M, Kröller-Schön S, Steven S. et al. Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. Hypertension 2014; 63 (02) 390-396
• 26 Seals DR, Kaplon RE, Gioscia-Ryan RA, LaRocca TJ. You're only as old as your arteries: translational strategies for preserving vascular endothelial function with aging. Physiology (Bethesda) 2014; 29 (04) 250-264
• 27 Epstein M. Aging and the kidney. J Am Soc Nephrol 1996; 7 (08) 1106-1122
• 28 Nabha L, Garbern JC, Buller CL, Charpie JR. Vascular oxidative stress precedes high blood pressure in spontaneously hypertensive rats. Clin Exp Hypertens 2005; 27 (01) 71-82
• 29 Lacy F, Kailasam MT, O'Connor DT, Schmid-Schönbein GW, Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension 2000; 36 (05) 878-884
• 30 Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 2001; 19 (07) 1245-1254
• 31 Grossman E. Does increased oxidative stress cause hypertension?. Diabetes Care 2008; 31 (Suppl. 02) S185-S189
• 32 Prasad K. Hypertension. In: Dieter RS, Dieter RA, Dieter III RA. eds. Peripheral Arterial Disease. New York, NY: The McGraw-Hill companies; 2009: 125-140
• 33 Bharadwaj LA, Prasad K. Mechanism of superoxide anion-induced modulation of vascular tone. Int J Angiol 2002; 11 (01) 23-29
• 34 Bharadwaj L, Prasad K. Mediation of H2O2-induced vascular relaxation by endothelium-derived relaxing factor. Mol Cell Biochem 1995; 149-150: 267-270
• 35 O'Mahony D, Bennett C, Green A, Sinclair AJ. Reduced baroreflex sensitivity in elderly humans is not due to efferent autonomic dysfunction. Clin Sci (Lond) 2000; 98 (01) 103-110
• 36 Seals DR, Esler MD. Human ageing and the sympathoadrenal system. J Physiol 2000; 528 (Pt 3): 407-417
• 37 Zemel MB, Sowers JR. Salt sensitivity and systemic hypertension in the elderly. Am J Cardiol 1988; 61 (16) 7H-12H
• 38 Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 2006; 15: 57-68
• 39 Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34
• 40 Tam XH, Shiu SW, Leng L, Bucala R, Betteridge DJ, Tan KC. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond) 2011; 120 (02) 81-89
• 41 Yonekura H, Yamamoto Y, Sakurai S. et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370 (Pt 3): 1097-1109
• 42 Koyama H, Shoji T, Yokoyama H. et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25 (12) 2587-2593
• 43 Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280 (05) E685-E694
• 44 Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006; 72 (11) 1493-1505
• 45 Reznikov LL, Waksman J, Azam T. et al. Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 2004; 61 (05) 324-336
• 46 Stassen M, Müller C, Arnold M. et al. IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-kappa B is decisively involved in the expression of IL-9. J Immunol 2001; 166 (07) 4391-4398
• 47 Bond M, Baker AH, Newby AC. Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999; 264 (02) 561-567
• 48 Fukami K, Yamagishi S, Coughlan MT. et al. Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. Diabetol Metab Syndr 2014; 6 (01) 86
• 49 Mohammed AM, Syeda K, Hadden T, Kowluru A. Upregulation of phagocyte-like NADPH oxidase by cytokines in pancreatic beta-cells: attenuation of oxidative and nitrosative stress by 2-bromopalmitate. Biochem Pharmacol 2013; 85 (01) 109-114
• 50 Yang D, Elner SG, Bian ZM, Till GO, Petty HR, Elner VM. Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res 2007; 85 (04) 462-472
• 51 Basta G, Lazzerini G, Massaro M. et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105 (07) 816-822
• 52 Yamagishi S, Inagaki Y, Okamoto T. et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002; 277 (23) 20309-20315
• 53 Sasaki T, Horiuchi S, Yamazaki M, Yui S. Induction of GM-CSF production of macrophages by advanced glycation end products of the Maillard reaction. Biosci Biotechnol Biochem 1999; 63 (11) 2011-2013
• 54 Sakata N, Meng J, Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 2000; 7 (03) 169-176
• 55 Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A 1990; 87 (22) 9010-9014
• 56 Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992; 90 (02) 439-446
• 57 Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J Clin Invest 1994; 93 (03) 1172-1178
• 58 Sutton G, Pugh D, Dhaun N. Developments in the role of endothelin-1 in atherosclerosis: a potential therapeutic target?. Am J Hypertens 2019; 32 (09) 813-815
• 59 Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318 (20) 1315-1321
• 60 Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 1995; 26 (06) 875-888
• 61 Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87 (02) 432-438
• 62 Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17 (10) 1289-1291
• 63 Rojas A, Romay S, González D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 2000; 86 (03) E50-E54
• 64 Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114 (06) 597-605
• 65 Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992; 90 (03) 1110-1115
• 66 Quehenberger P, Bierhaus A, Fasching P. et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 2000; 49 (09) 1561-1570
• 67 Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108 (07) 949-955
• 68 Wendt T, Harja E, Bucciarelli L. et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006; 185 (01) 70-77
• 69 Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 2009; 48 (10) 1190-1196
• 70 Prasad K, Mishra M. Mechanism of hypercholesterolemia-induced atherosclerosis. RCM 2022; 23 (06) 212
• 71 McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. Am J Hypertens 2007; 20 (03) 242-247
• 72 Wang X, Desai K, Clausen JT, Wu L. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 2004; 66 (06) 2315-2321
• 73 Uribarri J, Cai W, Peppa M. et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62 (04) 427-433
• 74 Vlassara H, Cai W, Goodman S. et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 2009; 94 (11) 4483-4491
• 75 Schram MT, Schalkwijk CG, Bootsma AH, Fuller JH, Chaturvedi N, Stehouwer CD. EURODIAB Prospective Complications Study Group. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. Hypertension 2005; 46 (01) 232-237
• 76 Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens 2009; 22 (01) 74-79
• 77 Semba RD, Sun K, Schwartz AV. et al; Health ABC Study. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with arterial stiffness in older adults. J Hypertens 2015; 33 (04) 797-803 , discussion 803
• 78 Accacha S, Rosenfeld W, Jacobson A. et al. Plasma advanced glycation end products (AGEs), receptors for AGEs and their correlation with inflammatory markers in middle school-age children. Horm Res Paediatr 2013; 80 (05) 318-327
• 79 Li SY, Du M, Dolence EK. et al. Aging induces cardiac diastolic dysfunction, oxidative stress, accumulation of advanced glycation endproducts and protein modification. Aging Cell 2005; 4 (02) 57-64
• 80 Chiang KH, Chen JW, Huang SS, Leu HB, Lin SJ, Huang PH. The ratio of AGE to sRAGE independently associated with albuminuria in hypertensive patients. BMC Endocr Disord 2018; 18 (01) 84
• 81 Mayer O, Seidlerová J, Filipovský J. et al. Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population. Hypertens Res 2016; 39 (04) 266-271
• 82 Geroldi D, Falcone C, Emanuele E. et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005; 23 (09) 1725-1729
• 83 Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001; 38 (4, suppl 1): S100-S106
• 84 Momma H, Niu K, Kobayashi Y. et al. Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study. Diabetol Metab Syndr 2014; 6 (01) 33
• 85 Dimitriadis K, Tsioufis C, Kasiakogias A. et al. Soluble receptor for advanced glycation end-product levels are related to albuminuria and arterial stiffness in essential hypertension. Nutr Metab Cardiovasc Dis 2013; 23 (04) 382-388
• 86 Li YM, Steffes M, Donnelly T. et al. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A 1996; 93 (09) 3902-3907
• 87 Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996; 39 (08) 946-951
• 88 Luevano-Contreras C, Chapman-Novakofski K. Dietary advanced glycation end products and aging. Nutrients 2010; 2 (12) 1247-1265
• 89 Franklin SS, Larson MG, Khan SA. et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103 (09) 1245-1249
• 90 Levine AB, Punihaole D, Levine TB. Characterization of the role of nitric oxide and its clinical applications. Cardiology 2012; 122 (01) 55-68
• 91 Nishiyama SK, Zhao J, Wray DW, Richardson RS. Vascular function and endothelin-1: tipping the balance between vasodilation and vasoconstriction. J Appl Physiol 2017; 122 (02) 354-360
• 92 Roberts AB, Heine UI, Flanders KC, Sporn MB. Transforming growth factor-beta. Major role in regulation of extracellular matrix. Ann N Y Acad Sci 1990; 580: 225-232
• 93 Matsuki K, Hathaway CK, Lawrence MG, Smithies O, Kakoki M. The role of transforming growth factor β1 in the regulation of blood pressure. Curr Hypertens Rev 2014; 10 (04) 223-238
• 94 Rodrigo R, González J, Paoletto F. The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res 2011; 34 (04) 431-440
• 95 Dandona P, Mohanty P, Ghanim H. et al. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 2001; 86 (01) 355-362
• 96 Lassègue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003; 285 (02) R277-R297
• 97 Rafieian-Kopaei M, Baradaran A, Rafieian M. Plants antioxidants: From laboratory to clinic. J Nephropathol 2013; 2 (02) 152-153
• 98 Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?. Hypertension 2004; 44 (03) 248-252
• 99 Kooy NW, Royall JA. Agonist-induced peroxynitrite production from endothelial cells. Arch Biochem Biophys 1994; 310 (02) 352-359
• 100 Elliott SJ, Lacey DJ, Chilian WM, Brzezinska AK. Peroxynitrite is a contractile agonist of cerebral artery smooth muscle cells. Am J Physiol 1998; 275 (05) H1585-H1591
• 101 Chabot F, Mitchell JA, Quinlan GJ, Evans TW. Characterization of the vasodilator properties of peroxynitrite on rat pulmonary artery: role of poly (adenosine 5′-diphosphoribose) synthase. Br J Pharmacol 1997; 121 (03) 485-490
• 102 Boin F, Erre GL, Posadino AM. et al. Oxidative stress-dependent activation of collagen synthesis is induced in human pulmonary smooth muscle cells by sera from patients with scleroderma-associated pulmonary hypertension. Orphanet J Rare Dis 2014; 9: 123
• 103 Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38 (3, pt. 2): 581-587
• 104 Staiculescu MC, Foote C, Meininger GA, Martinez-Lemus LA. The role of reactive oxygen species in microvascular remodeling. Int J Mol Sci 2014; 15 (12) 23792-23835
• 105 Anrather J, Racchumi G, Iadecola C. NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem 2006; 281 (09) 5657-5667
• 106 Cowling RT, Zhang X, Reese VC. et al. Effects of cytokine treatment on angiotensin II type 1A receptor transcription and splicing in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005; 289 (03) H1176-H1183
• 107 van Haaster MC, McDonough AA, Gurley SB. Blood pressure regulation by the angiotensin type 1 receptor in the proximal tubule. Curr Opin Nephrol Hypertens 2018; 27 (01) 1-7
• 108 Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis 2008; 196 (01) 9-21
• 109 Zhang ZH, Wei SG, Francis J, Felder RB. Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 2003; 284 (04) R916-R927
• 110 Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997; 37 (03) 240-249
• 111 Giardina JB, Green GM, Cockrell KL, Granger JP, Khalil RA. TNF-alpha enhances contraction and inhibits endothelial NO-cGMP relaxation in systemic vessels of pregnant rats. Am J Physiol Regul Integr Comp Physiol 2002; 283 (01) R130-R143
• 112 LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 2005; 46 (01) 82-86
• 113 Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19 (02) 149-154
• 114 Agita A, Alsagaff MT. Inflammation, Immunity, and Hypertension. Acta Med Indones 2017; 49 (02) 158-165
• 115 Braquet P, Hosford D, Braquet M, Bourgain R, Bussolino F. Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol 1989; 88 (1-2): 88-100
• 116 Tanase DM, Gosav EM, Radu S. et al. Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?. Int J Hypertens 2019; 2019: 3159283
• 117 Granger JP. An emerging role for inflammatory cytokines in hypertension. Am J Physiol Heart Circ Physiol 2006; 290 (03) H923-H924
• 118 DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10 (12, pt. 1): 1335-1341
• 119 Lang PP, Bai J, Zhang YL. et al. Blockade of intercellular adhesion molecule-1 prevents angiotensin II-induced hypertension and vascular dysfunction. Lab Invest 2020; 100 (03) 378-386
• 120 Kuwahara F, Kai H, Tokuda K. et al. Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension 2003; 41 (3, pt. 2): 819-823
• 121 Yin L, Bai J, Yu WJ, Liu Y, Li HH, Lin QY. Blocking VCAM-1 prevents angiotensin II-induced hypertension and vascular remodeling in mice. Front Pharmacol 2022; 13: 825459
• 122 Prasad K, Tiwari S. Therapeutic interventions for advanced glycation-end products and its receptor- mediated cardiovascular disease. Curr Pharm Des 2017; 23 (06) 937-943
• 123 Prasad K, Bhanumathy KK. AGE-RAGE axis in the pathophysiology of chronic lower limb ischemia and a novel strategy for its treatment. Int J Angiol 2020; 29 (03) 156-167
• 124 Prasad K. AGE-RAGE stress and coronary artery disease. Int J Angiol 2021; 30 (01) 4-14
• 125 Sri Hari TY, Sree Sudha TY, Varghese AM, Krishna Sasanka KSBS, Thangaraju P. A study of risk factors and complications in elderly hypertensive subjects. J Family Med Prim Care 2021; 10 (06) 2230-2234
• 126 Zhang Y, Yang H, Ren M. et al. Distribution of risk factors of hypertension patients in different age groups in Tianjin. BMC Public Health 2021; 21 (01) 247
• 127 Shukuri A, Tewelde T, Shaweno T. Prevalence of old age hypertension and associated factors among older adults in rural Ethiopia. Integr Blood Press Control 2019; 12: 23-31
• 128 Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, Chiu J. Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol 2004; 287 (02) H695-H703
• 129 Kenney MJ, Ganta CK. Autonomic nervous system and immune system interactions. Compr Physiol 2014; 4 (03) 1177-1200